Eubel Brady & Suttman Asset Management Inc. Raises Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Eubel Brady & Suttman Asset Management Inc. lifted its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 229,375 shares of the medical equipment provider’s stock after buying an additional 6,372 shares during the period. Zimmer Biomet comprises 3.6% of Eubel Brady & Suttman Asset Management Inc.’s portfolio, making the stock its 8th largest holding. Eubel Brady & Suttman Asset Management Inc.’s holdings in Zimmer Biomet were worth $24,894,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in ZBH. Chicago Partners Investment Group LLC increased its holdings in Zimmer Biomet by 3.3% during the fourth quarter. Chicago Partners Investment Group LLC now owns 2,894 shares of the medical equipment provider’s stock valued at $349,000 after buying an additional 92 shares during the last quarter. North Star Investment Management Corp. boosted its position in shares of Zimmer Biomet by 16.6% during the first quarter. North Star Investment Management Corp. now owns 669 shares of the medical equipment provider’s stock worth $88,000 after acquiring an additional 95 shares during the last quarter. First Bancorp Inc ME boosted its position in shares of Zimmer Biomet by 5.3% during the first quarter. First Bancorp Inc ME now owns 1,970 shares of the medical equipment provider’s stock worth $260,000 after acquiring an additional 100 shares during the last quarter. Ballentine Partners LLC boosted its position in shares of Zimmer Biomet by 2.6% during the first quarter. Ballentine Partners LLC now owns 3,957 shares of the medical equipment provider’s stock worth $522,000 after acquiring an additional 100 shares during the last quarter. Finally, Romano Brothers AND Company boosted its position in shares of Zimmer Biomet by 1.1% during the first quarter. Romano Brothers AND Company now owns 9,514 shares of the medical equipment provider’s stock worth $1,256,000 after acquiring an additional 100 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on ZBH. The Goldman Sachs Group began coverage on shares of Zimmer Biomet in a research report on Thursday, May 30th. They set a “neutral” rating and a $129.00 price objective for the company. Citigroup lowered their target price on shares of Zimmer Biomet from $134.00 to $120.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. Raymond James lowered their target price on shares of Zimmer Biomet from $138.00 to $128.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Morgan Stanley lowered their target price on shares of Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. Finally, Evercore ISI reaffirmed an “in-line” rating and issued a $113.00 price target on shares of Zimmer Biomet in a research note on Thursday, September 5th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $126.00.

Zimmer Biomet Stock Performance

ZBH opened at $104.83 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 0.63. The firm has a fifty day moving average price of $110.01 and a 200 day moving average price of $116.63. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $133.90. The stock has a market cap of $21.35 billion, a P/E ratio of 22.69, a P/E/G ratio of 1.92 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.02. The company had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.94 billion. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The firm’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.82 earnings per share. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.02 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend is Monday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 20.78%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.